Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

被引：30

作者：

Miller, AR ^{[1
]}

Etgen, GJ ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2003年 / 12卷 / 09期

关键词：

diabetes; PPAP; syndrome X; TZD;

D O I：

10.1517/eoid.12.9.1489.21821

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

As the incidence of Type 2 diabetes has reached near epidemic proportions, the quest for novel therapies; to combat this disorder has intensified dramatically. In recent years, the peroxisome proliferator-activated receptor (PPAR) family has received tremendous attention as perhaps an ideal target class to address the multiple metabolic anomalies associated with the diabetic state. This review focuses on a variety of novel PPAR approaches currently being investigated for Type 2 diabetes or the metabolic syndrome, including the highly potent selective PPAR agonists, PPAR combination agonists and alternative PPAR ligands.

引用

页码：1489 / 1500

页数：12

共 99 条

[1] Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-α activator [J].

Aasum, E ;

Belke, DD ;

Severson, DL ;

Riemersma, RA ;

Cooper, M ;

Andreassen, M ;

Larsen, TS .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 283 (03) :H949-H957

[2]

Al-Shamma H, 2001, DIABETES, V50, pA105

[3]

Animati F, 1996, MOL PHARMACOL, V50, P603

[4]

Araki K, 2000, DIABETES, V49, pA105

[5] Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].

Aronoff, S ;

Rosenblatt, S ;

Braithwaite, S ;

Egan, JW ;

Mathisen, AL ;

Schneider, RL .

DIABETES CARE, 2000, 23 (11) :1605-1611

[6] The mechanisms of action of PPARs [J].

Berger, J ;

Moller, DE .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435

[7] Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects [J].

Berger, J ;

Leibowitz, MD ;

Doebber, TW ;

Elbrecht, A ;

Zhang, B ;

Zhou, GC ;

Biswas, C ;

Cullinan, CA ;

Hayes, NS ;

Li, Y ;

Tanen, M ;

Ventre, J ;

Wu, MS ;

Berger, GD ;

Mosley, R ;

Marquis, R ;

Santini, C ;

Sahoo, SP ;

Tolman, RL ;

Smith, RG ;

Moller, DE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6718-6725

[8]

Berger Joel, 2002, Diabetes Technol Ther, V4, P163, DOI 10.1089/15209150260007381

[9] Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator [J].

Berger, JP ;

Petro, AE ;

Macnaul, KL ;

Kelly, LJ ;

Zhang, BB ;

Richards, K ;

Elbrecht, A ;

Johnson, BA ;

Zhou, GC ;

Doebber, TW ;

Biswas, C ;

Parikh, M ;

Sharma, N ;

Tanen, MR ;

Thompson, GM ;

Ventre, J ;

Adams, AD ;

Mosley, R ;

Surwit, RS ;

Moller, DE .

MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) :662-676

[10] Lipid abnormalities in the metabolic syndrome [J].

Eliot A. Brinton .

Current Diabetes Reports, 2003, 3 (1) :65-72

← 1 2 3 4 5 6 7 8 9 10 →